DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Metaproterenol (Metaproterenol Sulfate Inhalation) - Summary

 
 



METAPROTERENOL SUMMARY

Metaproterenol
Sulfate Inhalation
Solution USP
Sulfite-Free
Bronchodilator

Metaproterenol Sulfate Inhalation Solution USP is a unit-dose bronchodilator administered by oral inhalation with the aid of an intermittent positive pressure breathing apparatus (IPPB). It contains 0.4% or 0.6% metaproterenol sulfate in a sterile, acidic, aqueous solution containing edetate disodium, sodium chloride, hydrochloric acid and/or sodium hydroxide for pH adjustment.

Metaproterenol Sulfate Inhalation Solution is indicated as a bronchodilator for bronchial asthma and for reversible bronchospasm which may occur in association with bronchitis and emphysema.

Following controlled single dose studies by an intermittent positive pressure breathing apparatus (IPPB) and by hand bulb nebulizers, significant improvement (15% or greater increase in FEV1) occurred within 5 to 30 minutes and persisted for periods varying from 2 to 6 hours.

In these studies, the longer duration of effect occurred in the studies in which the drug was administered by IPPB, i.e. 6 hours versus 2 to 3 hours when administered by hand bulb nebulizer. In these studies the doses used were 0.3 mL by IPPB and 10 inhalations by hand bulb nebulizer.

In controlled repetitive dosing studies by IPPB and by hand bulb nebulizer the onset of effect occurred within 5 to 30 minutes and duration ranged from 4 to 6 hours. In these studies the doses used were 0.3 mL b.i.d. or t.i.d. when given by IPPB and 10 inhalations q.i.d. (no more often than q 4h) when given by hand bulb nebulizer. As in the single dose studies, effectiveness was measured as a sustained increase in FEV1 of 15% or greater. In these repetitive dosing studies there was no apparent difference in duration between the two methods of delivery.

During other clinical tolerance studies, metaproterenol was administered q.i.d. (by nebulizer) for periods of 60 and 90 days. On specified days before, during and after these open label trials, patients were referred to a laboratory where the effects of single doses of metaproterenol and isoproterenol on pulmonary function were recorded (in a double blind crossover controlled setting). Both drugs continued to exert significant improvement in function throughout this period of treatment.


See all Metaproterenol indications & dosage >>

NEWS HIGHLIGHTS


Page last updated: 2006-09-14

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014